Low long-term event rates are critical for acute myocardial infarction (AMI) patients, and XIENCE™ Stent findings show excellent early outcomes in AMI patients.2 Contributing to these results are several features of XIENCE™ Stent:
The XIENCE™ fluoropolymer exhibits improved anti-inflammatory characteristics compared to other drug-eluting stents (DES).3 This may be a key factor why the XIENCE™ Stent has such impressive safety data within 2 weeks post percutaneous coronary intervention (PCI) among AMI patients. Data show that—compared to immediately post intervention—XIENCE™ Stent reveals significant progression at 2 weeks post PCI2 in terms of:
2 Weeks Post PCI
A large, multicenter, real-world study revealed that the XIENCE™ Stent low clinical event rates at 1 year were sustained through 4 years—in both AMI and non-AMI patients.
XIENCE™ Stent also demonstrates safety among ST-elevation myocardial infarction (STEMI) patients, a subgroup of AMI patients. At 30 days, the rate of definite stent thrombosis (ST) with XIENCE™ Stent vs bare metal stents (BMS) was significantly lower: 0.4% vs 1.6%, p=0.02.
At 12 months 98% of patients with STEMI are free of target lesion revascularization (TLR).
The EXAMINATION trial looked at the AMI subgroup of STEMI patients, a subgroup of AMI patients. At both 1 and 5 years XIENCE™ Stents performed better than BMS in an all-comer population.6,7
A meta-analysis examined trials (n=1,581) comparing XIENCE™ second generation DES vs first generation DES—sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). XIENCE™ Stent conferred significantly lower rates of ST and target vessel revascularization (TVR) at 7 years.
One-year clinical outcomes from the XIENCE™ STEMI Registry further revealed that the XIENCE™ Stent was associated with a low incidence of clinical events—including stent thrombosis—even in a high-risk STEMI population.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?